2025年10月20日、28日和11月3日,根据Nasdaq规则,Aardvark治疗公司向新雇员发放了88 217股股票的股票选择权。 Aardvark Therapeutics granted stock options to new hires on Oct. 20, 28, and Nov. 3, 2025, under Nasdaq rules, for 88,217 shares.

2025年10月20日、28日和11月3日,根据Nasdaq规则,Aardvark治疗公司向新雇员发放了诱导股票选择权,以相当于12.28、12.00和10.39美元期末存货价值的价格授予88 217股股票。 Aardvark Therapeutics granted inducement stock options to new employees on Oct. 20, 28, and Nov. 3, 2025, under Nasdaq rules, awarding 88,217 shares at prices matching closing stock values of $12.28, $12.00, and $10.39. 4年以上可选择,一年之后为25%,此后为月度。 Options vest over four years, with 25% after one year and monthly thereafter. 该公司正在推进ARD-101,这是与Prader-Willi综合症有关的饥饿的第三阶段候选物,ARD-201是肥胖综合疗法,以饥饿作为独特的代谢途径。 The company is advancing ARD-101, a Phase 3 candidate for Prader-Willi Syndrome-related hunger, and ARD-201, a combination therapy for obesity, targeting hunger as a distinct metabolic pathway.